Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Natural killer cell lectin-like receptor subfamily K member 1 (NKG2D) is a major activating receptor found on natural killer (NK) cells, CD8+ T cells, and gamma-delta T cells [1]. Its ligands, which include MICA, MICB, and the ULBP family, are stress-induced proteins that are typically absent from healthy cells but highly expressed on the surface of various cancers, including hepatocellular carcinoma (HCC) [2]. The interaction between NKG2D and its ligands serves as a critical danger signal that triggers the innate and adaptive immune systems to eliminate transformed cells [3]. In therapeutic contexts such as Vax-NK, autologous NK cells are expanded and activated ex vivo to enhance their NKG2D-mediated recognition of tumor cells [4]. Once infused, these cells bind to NKG2D ligands on HCC cells, inducing targeted cell death through the secretion of cytotoxic granules containing perforin and granzymes [5]. However, tumors often evade this response by shedding surface ligands into a soluble form, which acts as a decoy and downregulates NKG2D expression on immune cells [6]. Current research focuses on overcoming this evasion and optimizing the NKG2D-ligand axis for more effective cancer immunotherapy [7].
Activation of NK cell cytotoxicity through the binding of the NKG2D receptor to stress-induced ligands (MICA/B, ULBPs) on the surface of tumor cells, leading to the release of perforin and granzymes.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell lectin-like receptor subfamily K member 1 (NKG2D) and its ligands (NKG2D/NKG2DL).